Other factors that were analyzed were age inyears, pre-treatment staging (stages I or II vs. III or IV), gender (male vs.female), weight lost in kg, BMI, tumor size in cm, tumor location (head/uncinateprocess vs. body/tail), albumin levels, CA 19.9 levels, ECOG status (0 or 1 vs.2, 3 or 4), decrease in NLR after palliation and post-palliation score (0 or 1vs. This evidence concerns the gene ALB and neoplasm.